Education
About Us
Working with TipRanks
Follow Us
Equasens (FR:EQS)
:EQS
EQS Stock Chart & Stats
Day’s Range― - ―
52-Week Range€30.55 - €56.70
Previous CloseN/A
Volume720.00
Average Volume (3M)6.93K
Market Cap
€778.06M
Enterprise Value€938.14M
Total Cash (Recent Filing)€47.42M
Total Debt (Recent Filing)€48.45M
Price to Earnings (P/E)21.5
Beta0.58
Next Earnings
Sep 26, 2025EPS EstimateN/A
Last Dividend Ex-Date
Jul 02, 2025Dividend Yield2.48%
Share Statistics
EPS (TTM)1.27
Shares Outstanding15,174,125
10 Day Avg. Volume6,975
30 Day Avg. Volume6,926
Financial Highlights & Ratios
PEG Ratio2.87
Price to Book (P/B)7.14
Price to Sales (P/S)0.00
P/FCF Ratio38.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€75.00Price Target Upside47.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Equasens News
Bulls Say, Bears Say
Bulls Say
Market MomentumOrganic growth should accelerate, and margins expand, benefiting from improving market momentum and product launches.
Organic GrowthEquasens had a strong Q1 with 5.9% organic growth, which should help the company regain some of the lost confidence from the investment community.
UndervaluationEquasens is materially undervalued given that its momentum is set to improve in 2025, with a potential for re-rating driven by improved end-customer health, new product launches, regulatory tailwinds, and easier comparison basis.
Bears Say
Growth ForecastManagement expects a positive momentum in H1, before an acceleration to nearly 10% organic growth in H2, driven by previous investments.
Market EnvironmentEquasens gaining market share in H2 in a better environment for French pharmacies.
Revenue ExpectationsEquasens saw its 4Q24 revenue come in 1% ahead of expectations.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
1.20%
Mutual Funds
― Other Institutional Investors
97.12% Public Companies and
Individual Investors
EQS FAQ
What was Equasens’s price range in the past 12 months?
Equasens lowest stock price was €30.55 and its highest was €56.70 in the past 12 months.
What is Equasens’s market cap?
Equasens’s market cap is €778.06M.
When is Equasens’s upcoming earnings report date?
Equasens’s upcoming earnings report date is Sep 26, 2025 which is in 70 days.
How were Equasens’s earnings last quarter?
Equasens released its earnings results on Mar 28, 2025. The company reported €1.267 earnings per share for the quarter, beating the consensus estimate of N/A by €1.267.
Is Equasens overvalued?
According to Wall Street analysts Equasens’s price is currently Undervalued.
Does Equasens pay dividends?
Equasens pays a Annually dividend of €1.25 which represents an annual dividend yield of 2.48%. See more information on Equasens dividends here
What is Equasens’s EPS estimate?
Equasens’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Equasens have?
Equasens has 15,174,125 shares outstanding.
What happened to Equasens’s price movement after its last earnings report?
Equasens reported an EPS of €1.267 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.84%.
Which hedge fund is a major shareholder of Equasens?
Currently, no hedge funds are holding shares in FR:EQS
Company Description
Equasens
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
EQS Stock 12 Month Forecast
Average Price Target
€75.00
▲(47.06%Upside)
Technical Analysis
Bastide le Confort Medical
―
Cegedim
―
LNA Sante SA
―
Ramsay Generale de Sante
―
Eurobio-Scientific SA
―